Constitutive activation of beta-catenin in uterine stroma and smooth muscle leads to the development of mesenchymal tumors in mice

Biology of Reproduction

Volumn 81, Issue 3, 2009, Pages 545-552

  Tanwar, Pradeep S ^a   Lee, Ho Joon ^a   Zhang, LiHua ^a   Zukerberg, Lawrence R ^b   Taketo, Makoto M ^c   Rueda, Bo R ^a   Teixeira, Jose M ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Adenomyosis; Beta catenin; Developmental biology; Endometrial stromal sarcoma; Hypertrophic scarring; Leiomyoma; Signal transduction; Uterine fibroids; Uterus; WNT signaling

Indexed keywords

BETA CATENIN; CRE RECOMBINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MUELLERIAN INHIBITING FACTOR; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

ADENOMYOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CARCINOGENIC ACTIVITY; DISEASE COURSE; ENDOMETRIUM HYPERPLASIA; ENZYME ACTIVATION; FEMALE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; MESENCHYME CELL; MESENCHYMOMA; MOUSE; MULTIPARA; MYOMETRIUM; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE; STEM CELL; STROMA; UTERUS; UTERUS FUNCTION;

ANIMALS; BETA CATENIN; CELL TRANSFORMATION, NEOPLASTIC; ENDOMETRIOSIS; FEMALE; LEIOMYOMA; MALE; MESODERM; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE, SMOOTH; STROMAL CELLS; TRANSCRIPTIONAL ACTIVATION; UTERINE DISEASES; UTERINE NEOPLASMS; UTERUS;

MAMMALIA; MUS;

EID: 69849087905     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.108.075648     Document Type: Article

References (49)

1. Cook JD, Walker CL. Treatment strategies for uterine leiomyoma: the role of hormonal modulation. Semin Reprod Med 2004; 22:105-111.
2. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science 2005; 308:1589-1592.
3. Mikels AJ, Nusse R. Wnts as ligands: processing, secretion and reception. Oncogene 2006; 25:7461-7468. (Pubitemid 44885745)
4. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14:1837-1851.
5. Ng TL, Gown AM, Barry TS, Cheang MC, Chan AK, Turbin DA, Hsu FD, West RB, Nielsen TO. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005; 18:68-74.
6. Jung CK, Jung JH, Lee A, Lee YS, Choi YJ, Yoon SK, Lee KY. Diagnostic use of nuclear beta-catenin expression for the assessment of endometrial stromal tumors. Mod Pathol 2008; 21:756-763. (Pubitemid 351744843)
7. Hrzenjak A, Tippl M, Kremser ML, Strohmeier B, Guelly C, Neumeister D, Lax S, Moinfar F, Tabrizi AD, Isadi-Moud N, Zatloukal K, Denk H. Inverse correlation of secreted frizzled-related protein 4 and beta-catenin expression in endometrial stromal sarcomas. J Pathol 2004; 204:19-27. (Pubitemid 39214478)
8. Parr BA, McMahon AP. Sexually dimorphic development of the mammalian reproductive tract requires Wnt-7a. Nature 1998; 395:707-710.
9. Miller C, Sassoon DA. Wnt-7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development 1998; 125:3201-3211. (Pubitemid 28434418)
10. Mericskay M, Kitajewski J, Sassoon D. Wnt5a is required for proper epithelial-mesenchymal interactions in the uterus. Development 2004; 131:2061-2072. (Pubitemid 38702039)
11. Xie H, Tranguch S, Jia X, Zhang H, Das SK, Dey SK, Kuo CJ, Wang H. Inactivation of nuclear Wnt-beta-catenin signaling limits blastocyst competency for implantation. Development 2008; 135:717-727.
12. Herington JL, Bi J, Martin JD, Bany BM. Beta-catenin (CTNNB1) in the mouse uterus during decidualization and the potential role of two pathways in regulating its degradation. J Histochem Cytochem 2007; 55:963-974. (Pubitemid 47293842)
13. Mohamed OA, Jonnaert M, Labelle-Dumais C, Kuroda K, Clarke HJ, Dufort D. Uterine Wnt/beta-catenin signaling is required for implantation. Proc Natl Acad Sci U S A 2005; 102:8579-8584. (Pubitemid 40862778)
14. Jamin SP, Arango NA, Mishina Y, Behringer RR. Genetic studies of MIS signalling in sexual development. Novartis Found Symp 2002; 244:157-164; discussion 164-158, 203-156, 253-1157
15. Arango NA, Szotek PP, Manganaro TF, Oliva E, Donahoe PK, Teixeira J. Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. Dev Biol 2005; 288:276-283. (Pubitemid 41713169)
16. Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, Taketo MM. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J 1999; 18:5931-5942. (Pubitemid 29515670)
17. Jamin SP, Arango NA, Mishina Y, Hanks MC, Behringer RR. Requirement of Bmpr1a for Mullerian duct regression during male sexual development. Nat Genet 2002; 32:408-410. (Pubitemid 35266116)
18. Teixeira J, He WW, Shah PC, Morikawa N, Lee MM, Catlin EA, Hudson PL, Wing J, Maclaughlin DT, Donahoe PK. Developmental expression of a candidate mullerian inhibiting substance type II receptor. Endocrinology 1996; 137:160-165. (Pubitemid 126424576)
19. Boerboom D, Paquet M, Hsieh M, Liu J, Jamin SP, Behringer RR, Sirois J, Taketo MM, Richards JS. Misregulated Wnt/beta-catenin signaling leads to ovarian granulosa cell tumor development. Cancer Res 2005; 65: 9206-9215. (Pubitemid 41507986)
20. Vainio S, Heikkila M, Kispert A, Chin N, McMahon AP. Female development in mammals is regulated by Wnt-4 signalling. Nature 1999; 397:405-409. (Pubitemid 29078900)
21. Lamminen S, Rantala I, Helin H, Rorarius M, Tuimala R. Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis. Gynecol Obstet Invest 1992; 34:111-114.
22. Arici A, Sozen I. Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril 2000; 73:1006-1011. (Pubitemid 30227527)
23. Catherino WH, Leppert PC, Stenmark MH, Payson M, Potlog-Nahari C, Nieman LK, Segars JH. Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. Genes Chromosomes Cancer 2004; 40:204-217. (Pubitemid 38703097)
24. Chegini N, Ma C, Tang XM, Williams RS. Effects of GnRH analogues, 'add-back' steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression. Mol Hum Reprod 2002; 8:1071-1078.
25. Dou Q, Zhao Y, Tarnuzzer RW, Rong H, Williams RS, Schultz GS, Chegini N. Suppression of transforming growth factor-beta (TGF beta) and TGF beta receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy. J Clin Endocrinol Metab 1996; 81:3222-3230. (Pubitemid 26296192)
26. Lee BS, Nowak RA. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab 2001; 86:913-920.
27. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-484.
28. Everitt JI, Wolf DC, Howe SR, Goldsworthy TL, Walker C. Rodent model of reproductive tract leiomyomata. Clinical and pathological features. Am J Pathol 1995; 146:1556-1567.
29. Brody JR, Cunha GR. Histologic, morphometric, and immunocytochemical analysis of myometrial development in rats and mice, I: normal development. Am J Anat 1989; 186:1-20.
30. Rushing RS, Shajahan S, Chendil D, Wilder JL, Pulliam J, Lee EY, Ueland FR, van Nagell JR, Ahmed MM, Lele SM. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of KIT. Gynecol Oncol 2003; 91:9-14. (Pubitemid 37188589)
31. Erdogan G, Bassorgun CI, Pestereli HE, Simsek T, Karaveli S. KIT protein expression in uterine and ovarian mesenchymal tumours. APMIS 2007; 115:204-209. (Pubitemid 46426648)
32. D'Armiento J, Imai K, Schiltz J, Kolesnekova N, Sternberg D, Benson K, Pardo A, Selman M, Smolarek T, Vundavalli M, Sonnet J, Szabolcs M, Chada K. Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis. Cancer Res 2007; 67:1902-1909. (Pubitemid 46424205)
33. Zaidi MR, Okada Y, Chada KK. Misexpression of full-length HMGA2 induces benign mesenchymal tumors in mice. Cancer Res 2006; 66:7453-7459. (Pubitemid 44289198)
34. Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T, Ishiguro S, Nakamura Y, Miyoshi Y. Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res 1998; 58: 1021-1026. (Pubitemid 28182473)
35. Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, Murata M, Shimano T, Nakamura Y. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998; 58:2524-2527. (Pubitemid 28275419)
36. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998; 58:3526-3528. (Pubitemid 28376543)
37. Wei J, Chiriboga L, Mizuguchi M, Yee H, Mittal K. Expression profile of tuberin and some potential tumorigenic factors in 60 patients with uterine leiomyomata. Mod Pathol 2005; 18:179-188. (Pubitemid 40188624)
38. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the FRAP1 pathway. Curr Opin Cell Biol 2005; 17:596-603.
39. Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM. Inhibition of the FRAP1C1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci U S A 2008; 105: 13544-13549.
40. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007; 11:321-333. (Pubitemid 46518315)
41. Leppert PC, Catherino WH, Segars JH. A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. Am J Obstet Gynecol 2006; 195:415-420.
42. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3:349-363. (Pubitemid 34619269)
43. Hoffman PJ, Milliken DB, Gregg LC, Davis RR, Gregg JP. Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis. Fertil Steril 2004; 82:639-649.
44. Luo X, Ding L, Xu J, Chegini N. Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology 2005; 146:1097-1118. (Pubitemid 40289299)
45. Zhao Y, Wen Y, Polan ML, Qiao J, Chen BH. Increased expression of latent TGF-beta binding protein-1 and fibrillin-1 in human uterine leiomyomata. Mol Hum Reprod 2007; 13:343-349. (Pubitemid 47061645)
46. Armour A, Scott PG, Tredget EE. Cellular and molecular pathology of HTS: basis for treatment. Wound Repair Regen 2007; 15(suppl 1):S6-S17. (Pubitemid 47301668)
47. Moinfar F, Azodi M, Tavassoli FA. Uterine sarcomas. Pathology 2007; 39:55-71.
48. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007; 369:1731-1741.
49. Jeong JW, Lee HS, Franco HL, Broaddus RR, Taketo MM, Tsai SY, Lydon JP, Demayo FJ. Beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus. Oncogene 2009; 28:31-40.